IL6R and triple-negative breast carcinoma: Currently, there is an ongoing EMPOWER (NCT04333706) clinical trial of the combination of sarilumab (IL-6R inhibitor) plus capecitabine in triple-negative breast cancer patients in stage I-III with high-risk residual disease [60].